BASAL INSULIN IN TYPE 2 DIABETES TREATMENT, WHAT'S NEXT? (AS-108)

Thursday, October 26, 2023

12:30 – 13:30 EST

Location: Palais, 517D

Target Audience: Endocrinologists, Diabetologists, Internists, Family Physicians , Allied Health Professionals, Residents

Chair : AS(s)

Harpreet S. Bajaj, MD, MPH, ECNU, FACE (he/him/his)

Endocrinologist & Medical Director, Endocrine and Metabolic Research
LMC Healthcare
Diabetes Canada

Presenter : AS(s)

SC

Sandra Cooke-Hubley
Tina Kader
Loredana Talos (she/her/hers)

Nurse Practitioner Adult Care - Endocrinology
Mcgill University Health Center
Mcgill University Health Center
Gihane Zarifa (she/her/hers)

MD, CCFP, FCFP, Msc. Diabetes Lead MD, Credit Valley FHT
Credit Valley Family Health Team
University of Toronto

Disclosure(s):

Harpreet S. Bajaj, MD, MPH, ECNU, FACE: Amgen: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Anji: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated); AstraZeneca: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated); Boehringer Ingelheim: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Eli Lilly: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Kowa: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated); Novartis: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Novo Nordisk: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Pfizer: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)

Tina Kader: No relevant disclosure to display

Loredana Talos: No financial relationships to disclose

Gihane Zarifa: Abbott: Speaker/Honoraria (Ongoing); Eli Lilly: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Novonordisk: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing)

Learning Objectives / Objectifs d'apprentissage:

At the end of this session participants will be able to / Au terme de cette conférence, vous serez:

provide a historical perspective on the innovation in basal insulin therapy since the discovery of insulin over 100 years ago.;
understand when to initiate basal insulin in 2023 and outline the challenges with insulin initiation; and
explain the efficacy and safety of once weekly basal to daily basal insulin in type 2 diabetes.

This program was co-developed by the Canadian Society of Endocrinology and Metabolism and Novo Nordisk Canada and was planned to achieve scientific integrity, objectivity, and balance.